NewBiologix Licences Xcell-Eng-HEK293 Cell Line to Recipharm
Share this article
NewBiologix, a Biopôle-based (Vaud)Swiss biotech innovator, has granted a non-exclusive licence to Recipharm Advanced Bio.
The agreement gives Recipharm access to NewBiologix’s Xcell-Eng-HEK293 cell lines, enabling the efficient production of recombinant Adeno-Associated Viruses (rAAVs) for cell and gene therapies.
The licensed cell lines offer high-yield, GMP-ready viral production, accelerating the path to clinical trials. Combined with Recipharm’s AAV manufacturing platform, the technology delivers industry-leading results, including >2E15 vg/L titers and >95% full capsids, across over 10 rAAV serotypes.
This partnership supports scalable, cost-effective, and high-purity gene therapy manufacturing, with a fully integrated offering from research to GMP production. It also reinforces NewBiologix’s goal to lead in gene therapy solutions and advances Recipharm’s strategy to reduce development costs and improve access to life-saving therapies.
➡️ Source: NewBiologix